The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 28 March 2006, www.theannals.com, DOI 10.1345/aph.1G378.
 The Annals of Pharmacotherapy: Vol. 40, No. 4, pp. 674-682. DOI 10.1345/aph.1G378
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nguyen, L. N
Right arrow Articles by Guthrie, S. K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nguyen, L. N
Right arrow Articles by Guthrie, S. K

PSYCHIATRY

Risperidone Treatment of Bipolar Mania

Lisa N Nguyen, PharmD

Primary Care Resident, Primary Care Pharmacy Department, Providence Medical Group, Beaverton, OR

Sally K Guthrie, PharmD

Associate Professor, Department of Psychiatry, College of Pharmacy, University of Michigan, Ann Arbor, MI

Reprints:Dr. Guthrie, University of Michigan College of Pharmacy, College of Pharmacy Building, 428 Church St., Ann Arbor, MI 48109-1065, fax 734/763-4480,salgut{at}umich.edu

OBJECTIVE: To review clinical trial evidence regarding the efficacy and safety of risperidone for the treatment of bipolar mania.

DATA SOURCES: Articles were identified through searches of PubMed (1950-August 2005), EMBASE (1988-August 2005 week 37), and International Pharmaceutical Abstracts (1970-August 2005) databases using the key words risperidone, atypical antipsychotics, and bipolar mania. Additional references were found through review of bibliographies of identified articles. PubMed searches for efficacy and safety were limited to clinical trials.

STUDY SELECTION AND DATA EXTRACTION: Six randomized trials and 6 observational studies of risperidone monotherapy or combination therapy for bipolar mania in adults were selected.

DATA SYNTHESIS: Randomized, placebo-controlled and observational trials reported that risperidone monotherapy decreases manic symptoms in patients with a moderate severity of mania, as determined by change in Young Mania Rating Scale (YMRS) scores. Adverse effects observed in monotherapy trials included somnolence, extrapyramidal symptoms (EPS), and weight gain. Clinical trials of risperidone in combination with other mood stabilizers (ie, lithium, valproate, carbamazepine, topiramate) also reported decreases in YMRS scores in patients with moderate and severe manic symptoms.

CONCLUSIONS: Risperidone monotherapy or adjunctive therapy with other first-line mood stabilizers may be effective for the treatment of acute bipolar mania in adults with moderate severity of mania. The use of risperidone as monotherapy in severe mania or in maintenance treatment remains to be elucidated.

Key Words: atypical antipsychotics, bipolar mania, risperidone

Published Online, March 28, 2006. www.theannals.com, DOI 10.1345/aph.1G378




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.